|
|
Treatment for General CMV Disease in
Children:
A phase I, open-label trial (ACTG 226) of oral ganciclovir for the
treatment of
general CMV in children between the ages of 2 weeks and 20 years is
currently
underway. Upon completing induction therapy with a single dose of
intravenous
ganciclovir, patients will be randomized to receive one of four doses
of the oral
formulation in either syrup or pill form.
Go to the Cytomegalovirus Menu
Go to the Viral Infections Menu
Go to the Opportunistic Infections
Menu
Go to the HIVpositive.com Main Menu